Radiofrequency ablation for hepatocellular carcinoma
Open Access
- 7 August 2013
- journal article
- review article
- Published by Taylor & Francis Ltd in International Journal of Hyperthermia
- Vol. 29 (6), 558-568
- https://doi.org/10.3109/02656736.2013.821528
Abstract
Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related mortality worldwide. Unfortunately, only 20% of HCC patients are amenable to curative therapy (liver transplantation or surgical resection). Locoregional therapies such as radiofrequency ablation (RFA), percutaneous ethanol injection, microwave coagulation therapy, and transcatheter arterial chemoembolisation play a key role in the management of HCC. The choice of the treatment modality depends on the size of the tumour, tumour location, anatomic considerations and the number of tumours present and liver function. RFA therapy for HCC can be performed safely using a percutaneous, laparoscopic, or an open approach, even in patients with poor functional reserve. Since the introduction of RFA, several randomised controlled trials and non-randomised studies comparing RFA and other therapies for HCC have been conducted. In addition, in the last decade there have been technical advances in RFA therapy for HCC, resulting in significant improvement in the prognosis of HCC patients treated with this modality. In this review, we primarily focus on percutaneous RFA therapy for HCC and refer to current knowledge and future perspectives for this therapy. We also discuss new emerging ablation techniques.Keywords
This publication has 100 references indexed in Scilit:
- Epidemiology of Viral Hepatitis and Hepatocellular CarcinomaGastroenterology, 2012
- Radiofrequency Ablation for Hepatocellular Carcinoma: 10-Year Outcome and Prognostic FactorsThe American Journal of Gastroenterology, 2012
- Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinomaBMC Gastroenterology, 2010
- Irreversible Electroporation Therapy in the Liver: Longitudinal Efficacy Studies in a Rat Model of Hepatocellular CarcinomaCancer Research, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Effectiveness of real‐time virtual sonography‐guided radiofrequency ablation treatment for patients with hepatocellular carcinomasHepatology Research, 2008
- Chemoembolization Combined With Radiofrequency Ablation for Patients With Hepatocellular Carcinoma Larger Than 3 cmJAMA, 2008
- Single hepatocellular carcinoma ranging from 3 to 5cm: radiofrequency ablation or resection?HPB, 2007
- A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular CarcinomaJNCI Journal of the National Cancer Institute, 2005
- Radiofrequency ablation versus surgical resection for single nodule hepatocellular carcinoma: Long‐term outcomesHPB, 2005